H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Lyell Immunopharma (LYEL) to $10 from $1 and keeps a Neutral rating on the shares. The firm adjusted the company’s model to account for the 20-for-1 reverse split earlier this month.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYEL:
- Lyell Immunopharma Announces Promising CAR T-Cell Trial Data
- Lyell Immunopharma’s LYL314 shows strong response in Phase 1/2 lymphoma trial
- Lyell Immunopharma Expands Board, Appoints New Director
- Lyell Immunopharma appoints David Shook as CMO, Mark Meltz as general counsel
- Lyell Immunopharma trading resumes